AU4033900A - Compositions and methods for treating cell proliferation disorders - Google Patents

Compositions and methods for treating cell proliferation disorders

Info

Publication number
AU4033900A
AU4033900A AU40339/00A AU4033900A AU4033900A AU 4033900 A AU4033900 A AU 4033900A AU 40339/00 A AU40339/00 A AU 40339/00A AU 4033900 A AU4033900 A AU 4033900A AU 4033900 A AU4033900 A AU 4033900A
Authority
AU
Australia
Prior art keywords
compositions
methods
cell proliferation
proliferation disorders
treating cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40339/00A
Other languages
English (en)
Inventor
Jacques Banchereau
Francois Fossiez
Herve Fridman
Serge J. E Lebecque
Eric Tartour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Merck Sharp and Dohme LLC
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Curie
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Institut Curie, Schering Corp filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU4033900A publication Critical patent/AU4033900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU40339/00A 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders Abandoned AU4033900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99401191 1999-05-17
EP99401191A EP1053751A1 (en) 1999-05-17 1999-05-17 Compositions and methods for treating cell proliferation disorders
PCT/US2000/008081 WO2000069463A1 (en) 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders

Publications (1)

Publication Number Publication Date
AU4033900A true AU4033900A (en) 2000-12-05

Family

ID=8241974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40339/00A Abandoned AU4033900A (en) 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders

Country Status (6)

Country Link
EP (2) EP1053751A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004500325A (cg-RX-API-DMAC7.html)
AU (1) AU4033900A (cg-RX-API-DMAC7.html)
CA (1) CA2373938A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA01011923A (cg-RX-API-DMAC7.html)
WO (1) WO2000069463A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350687T3 (es) * 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101374864A (zh) * 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
MY162790A (en) 2011-01-14 2017-07-14 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AU2017261360A1 (en) 2016-05-06 2018-11-29 Exicure Operating Company Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
EP4087858A1 (en) * 2020-01-10 2022-11-16 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634726T2 (de) * 1995-07-19 2006-05-04 Genetics Institute, LLC, Cambridge Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
WO1999014240A1 (en) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
DE29820466U1 (de) * 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1251872A1 (en) 2002-10-30
MXPA01011923A (es) 2003-10-15
CA2373938A1 (en) 2000-11-23
EP1053751A1 (en) 2000-11-22
JP2004500325A (ja) 2004-01-08
WO2000069463A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
AU8003800A (en) Methods and compositions for treating neurobehavioral disorders
HUP0201436A3 (en) Methods and compositions for treating solid tumors
AUPQ419099A0 (en) Novel compositions and methods
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
AU1296099A (en) Methods and compositions for treating dermatoses
AU3877900A (en) Compositions and methods for preventing and treating sexual dysfunctions
AU5294100A (en) Method and compositions for treating the inflammatory response
AU2327599A (en) Compositions and methods for treating autoimmune diseases
AU5170900A (en) Cell proliferation inhibitors
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
AU1359801A (en) Methods and compositions for treating reward deficiency syndrome
AU6056500A (en) Process and composition for temporarily suppressing pain
AU4697600A (en) Methods for increasing t cell proliferation
AU4859399A (en) Compositions and methods for treating papillomavirus-infected cells
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
AU6094200A (en) Nor gene compositions and methods for use thereof
AU6006800A (en) Treating cells
AU2002305700A1 (en) Composition and method for treating cells
EP1646395B8 (en) Methods and compositions for regulating lymphocyte activity
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders
AU5097099A (en) Methods and compositions for cancer treatment
AU7604100A (en) Composition and method for treating burns
AU5169200A (en) Methods and compositions for treating breakthrough pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase